Skip to main content
Opens in new window
NHS Wales
NHS 111 Wales
Skip Navigation
Accessibility
Contact us
Cymraeg
Cymraeg
All...
Search
All Wales Therapeutics and Toxicology Centre
Search
Cymraeg
Cymraeg
Menu
Home
Accessing medicines
Show Submenu For Accessing medicines
Access to medicines in Wales
Medicine recommendations
Make a submission
Medicines optimisation and safety
Show Submenu For Medicines optimisation and safety
Medicines optimisation guidance, resources and data
Yellow Card Centre Wales
Welsh National Poisons Unit
Work in progress
News, meetings and events
Show Submenu For News, meetings and events
News
Meetings
Events
About us
Show Submenu For About us
Who we are
What we do
Our committees
Who we work with
Our research
Our reports and strategies
Sustainability
Contact us
More
×
TA982: Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over
TA979: Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation
TA971: Remdesivir and tixagevimab plus cilgavimab for treating COVID-19
TA970: Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments
TA962: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
TA959: Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis
TA958: Ritlecitinib for treating severe alopecia areata in people 12 years and over
TA952: Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations
TA939: Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer
TA931: Zanubrutinib for treating chronic lymphocytic leukaemia
TA918: Bimekizumab for treating axial spondyloarthritis
TA912: Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease
TA787: Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable
TA786: Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies
TA704: Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies
TA705: Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer
TA706: Ozanimod for treating relapsing–remitting multiple sclerosis
TA707: Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer
TA708: Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis
TA710: Ravulizumab for treating atypical haemolytic uraemic syndrome
TA709: Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
TA713: Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy
TA712: Enzalutamide for treating hormone-sensitive metastatic prostate cancer
TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
TA718: Ixekizumab for treating axial spondyloarthritis
TA719: Secukinumab for treating non-radiographic axial spondyloarthritis
TA700: Selinexor with low-dose dexamethasone for treating refractory multiple myeloma (terminated appraisal)
TA716: Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
TA722: Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement
TA720: Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma
NHS Wales
NHS 111 Wales
Accessibility
Contact us
All...
Search
Listen
Home
›
Links
›
NICE TAs
NICE TAs
01/05/2020
TA591: Letermovir for preventing cytomegalovirus disease after a stem cell transplant
30/04/2020
TA485: Sarilumab for moderate to severe rheumatoid arthritis
30/04/2020
TA511: Brodalumab for treating moderate to severe plaque psoriasis
30/04/2020
TA490: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy
29/04/2020
TA480: Tofacitinib for moderate to severe rheumatoid arthritis
29/04/2020
TA616: Cladribine for treating relapsing–remitting multiple sclerosis
29/04/2020
TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis
29/04/2020
TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
29/04/2020
TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
29/04/2020
TA530: Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy
29/04/2020
TA512: Tivozanib for treating advanced renal cell carcinoma
29/04/2020
TA555: Regorafenib for previously treated advanced hepatocellular carcinoma
29/04/2020
TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer
29/04/2020
TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
29/04/2020
TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C
29/04/2020
TA588: Nusinersen for treating spinal muscular atrophy
29/04/2020
TA539: Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours
29/04/2020
TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
29/04/2020
TA517: Avelumab for treating metastatic Merkel cell carcinoma
28/04/2020
TA518: Tocilizumab for treating giant cell arteritis
7
8
9
10
11
12
13
14
15
16
17
Follow AWTTC: